Encapsulation of the Dinuclear Trithiolato-Bridged Arene Ruthenium Complex Diruthenium-1 in an Apoferritin Nanocage: Structure and Cytotoxicity.
Petruk, G., Monti, D.M., Ferraro, G., Pica, A., D'Elia, L., Pane, F., Amoresano, A., Furrer, J., Kowalski, K., Merlino, A.(2019) ChemMedChem 14: 594-602
- PubMed: 30674089 
- DOI: https://doi.org/10.1002/cmdc.201800805
- Primary Citation of Related Structures:  
6GXJ - PubMed Abstract: 
The effects of encapsulating the cytotoxic dinuclear trithiolato-bridged arene ruthenium complex [(η 6 -p-MeC 6 H 4 iPr) 2 Ru 2 (μ 2 -S-p-C 6 H 4 tBu) 3 ]Cl (DiRu-1) within the apoferritin (AFt) nanocage were investigated. The DiRu-1-AFt nanocarrier was characterized by UV/Vis spectroscopy, ICP-MS, CD and X-ray crystallography. In contrast to previously reported Au- and Pt-based drug-loaded AFt carriers, we found no evidence of direct interactions between DiRu-1 and AFt. DiRu-1-AFt is cytotoxic toward immortalized murine BALB/c-3T3 fibroblasts transformed with SV40 virus (SVT2) and human epidermoid carcinoma A431 malignant cells, and exhibits moderate selectivity for these cancer cells over normal BALB/c-3T3 cells. DiRu-1-AFt triggers the production of reactive oxygen species, depolarization of mitochondrial membrane potential, and induces cell death via p53-mediated apoptosis. Comparison between our data and previous results suggests that the presence of specific interactions between a metal-based drug and AFt within the protein cage is not essential for drug encapsulation.
Organizational Affiliation: 
Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario di Monte Sant'Angelo, via Cinthia 21, 80126, Naples, Italy.